Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3724 in Relapsed/Refractory CLL/SLL
NCT02556346Phase 1Withdrawn
- Sponsor
- Molecular Templates, Inc.
- Start
- Nov 2015
- Primary completion
- Aug 2016
- Modality
- Immunotoxins, Fc-Fusion Proteins
01
Overview
Phase 1, open-label trial of MT-3724 in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (5 arms), sponsored by Molecular Templates, Inc. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 24 months. Planned start Nov 2015; status: withdrawn.
02
Drugs
MT-3724
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02556346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02556346.